Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04330144|
Recruitment Status : Not yet recruiting
First Posted : April 1, 2020
Last Update Posted : April 1, 2020
There is no known definite treatment after exposure to SARS-CoV-2, but the some animal and clinical trials confirmed the efficacy of hydroxychloroquine (HCQ) or chloroquine against SARS-CoV-2. Thus, in this study, we aim to evaluate the efficacy and safety of hydroxychloroquine as post exposure prophylaxis for SARS-CoV-2.
- Primary end point: comparison the rate of COVID-19 between PEP with HCQ and control group.
- Secondary end point: Comparison of the rate of COVID-19 according to the contact level (time, place, degree of wearing personal protective equipment).
- Safety comparison: Safety verification by identifying major side effects in the HCQ group."
|Condition or disease||Intervention/treatment||Phase|
|Contact Person From COVID-19 Confirmed Patient||Drug: Hydroxychloroquine as post exposure prophylaxis Other: Others(No intervention)||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||2486 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||A Study of Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)|
|Estimated Study Start Date :||April 1, 2020|
|Estimated Primary Completion Date :||March 30, 2021|
|Estimated Study Completion Date :||March 30, 2022|
|Experimental: administration of hydroxychloroquine as PEP||
Drug: Hydroxychloroquine as post exposure prophylaxis
1day: Hydroxychloroquine 800mg Qd po 2-5dy: Hydroxychloroquine 400mg Qd po
|Active Comparator: control with no PEP||
Other: Others(No intervention)
No treatment. Close monitoring and quarantine.
- The rate of COVID-19 [ Time Frame: PCR test of COVID-19 at 14 days after the contact from confirmed case ]After postexposure prophylaxis, the rate of COVID-19 conversion between two groups
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04330144
|Contact: Yong Goo Song, Professor||82-2-2019-3310 ext firstname.lastname@example.org|
|Principal Investigator:||Yong Goo Song, Professor||Gangnam Severance Hospital|